2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology 2020, 21: 655-663. PMID: 32251621, PMCID: PMC7380514, DOI: 10.1016/s1470-2045(20)30111-x.Peer-Reviewed Original ResearchConceptsBrain metastasis responseYale Cancer CenterPD-L1 expressionPhase 2 trialUntreated brain metastasesBrain metastasesAdrenal insufficiencyAdverse eventsMetastasis responseCNS diseaseCancer CenterCohort 2Cohort 1Eastern Cooperative Oncology Group performance statusTreatment-related serious adverse eventsModified Response Evaluation CriteriaStage IV NSCLCTreatment-related deathsAcute kidney injuryPD-1 blockadeSerious adverse eventsSolid Tumors criteriaPhase 2 studyProportion of patientsResponse Evaluation Criteria
2012
Administration of Vincristine in a Patient with Machado-Joseph Disease
Colpo A, Wilson FH, Nardi V, Hochberg E. Administration of Vincristine in a Patient with Machado-Joseph Disease. Oncology 2012, 82: 165-167. PMID: 22433430, PMCID: PMC3701890, DOI: 10.1159/000336602.Peer-Reviewed Original ResearchConceptsMachado-Joseph diseaseChemotherapy-induced peripheral neurotoxicityDose-limiting side effectVinca alkaloidsSevere vincristine neurotoxicityAdministration of vincristinePeripheral neurotoxicitySpinocerebellar ataxia type 3Vincristine neurotoxicityNeurological symptomsAtaxia type 3Side effectsHereditary neuropathyAntineoplastic drugsType 3NeurotoxicityDiseaseSignificant numberNeuropathyExacerbationPatientsVincristineSymptomsAdministration
2004
A Cluster of Metabolic Defects Caused by Mutation in a Mitochondrial tRNA
Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A Cluster of Metabolic Defects Caused by Mutation in a Mitochondrial tRNA. Science 2004, 306: 1190-1194. PMID: 15498972, PMCID: PMC3033655, DOI: 10.1126/science.1102521.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingAnticodonBody Mass IndexCluster AnalysisCytidineExtrachromosomal InheritanceFemaleHumansHypercholesterolemiaHypertensionMagnesiumMaleMetabolic SyndromeMiddle AgedMitochondriaMitochondria, MuscleMuscle Fibers, SkeletalMutationPedigreePhenotypeRNARNA, MitochondrialRNA, Transfer, IleSyndromeThymidineUridine